Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort
| Title: | Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort |
|---|---|
| Authors: | Andrea‐Hermina Györfi; Tim Filla; Amin Polzin; Koray Tascilar; Maya Buch; Monique Tröbs; Alexandru‐Emil Matei; Paolo Airo; Alexandra Balbir‐Gurman; Frederic Kuwert; Carina Mihai; Anna Kabala; Hanna Graßhoff; Julia Callaghan; Yohei Isomura; Jennifer Mansour; Julia Spierings; Anders Heiervang Tennoe; Enrico Selvi; Valeria Riccieri; Anna‐Maria Hoffmann‐Vold; Christina Bergmann; Georg Schett; Nicolas Hunzelmann; Jacob M. van Laar; Lesley Ann Saketkoo; Masataka Kuwana; Elise Siegert; Gabriela Riemekasten; Oliver Distler; Tessa du Four; Vanessa Smith; Marie‐Elise Truchetet; Jörg H. W. Distler |
| Source: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 14, Iss 5 (2025) |
| Publisher Information: | Wiley, 2025. |
| Publication Year: | 2025 |
| Collection: | LCC:Diseases of the circulatory (Cardiovascular) system |
| Subject Terms: | EUSTAR cohort; mortality; risk factors; systemic sclerosis; systemic sclerosis primary heart involvement; Diseases of the circulatory (Cardiovascular) system; RC666-701 |
| Description: | Background Systemic sclerosis (SSc) primary heart involvement (SSc‐pHI) is one of the leading causes of mortality in SSc. We aimed to evaluate risk factors for SSc‐pHI and its progression and the outcomes in the EUSTAR (European Scleroderma Trials and Research) cohort. Methods SSc‐pHI was defined according to the World Scleroderma Foundation/Heart Failure Association definition. Data from 5741 patients with SSc in the EUSTAR cohort were analyzed. Additional cardiovascular data were collected from a subcohort of 838 patients with SSc. Lasso regression was used for risk factor analyses. Kaplan–Meier estimator was used for survival analyses. Progression of SSc‐pHI was evaluated by a study definition developed by rheumatology and cardiology experts. Results Risk factors for the presence of SSc‐pHI comprised skeletal muscle atrophy (odds ratio [OR], 2.00 [95% CI, 1.00–2.68]), age (OR, 1.91 [95% CI, 1.73–2.03]), male sex (OR, 1.77 [95% CI, 1.42–2.05]), swollen joints (OR, 1.70 [95% CI, 1.47–1.98]), skeletal muscle weakness (OR, 1.38 [95% CI, 1.00–1.85]), and tendon friction rubs (OR, 1.46 [95% CI, 1.00–1.77]) (n=3276). Telangiectasia (OR, 2.10 [95% CI, 1.38–2.72]), intestinal symptoms (OR, 1.70 [95% CI, 1.04–2.42]), age (OR, 1.47 [95% CI, 1.21–1.62]), and antitopoisomerase I antibodies (OR, 1.37 [95% CI, 1.00–1.77]) were associated with an increased risk for new onset of SSc‐pHI (n=1000). Survival rate was significantly lower in patients with SSc‐pHI than in those without (P value |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2047-9980 |
| Relation: | https://doaj.org/toc/2047-9980 |
| DOI: | 10.1161/JAHA.124.036730 |
| Access URL: | https://doaj.org/article/9721dfa89a044eecb0eceab7908d2c88 |
| Accession Number: | edsdoj.9721dfa89a044eecb0eceab7908d2c88 |
| Database: | Directory of Open Access Journals |